MCID: GST030
MIFTS: 41

Gastrinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrinoma

MalaCards integrated aliases for Gastrinoma:

Name: Gastrinoma 12 52 42 14 69
Gastrin Secreting Tumor 12
Gastrinoma, Malignant 69
Malignant Gastrinoma 12
Gastrin Cell Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5577
MeSH 42 D015408
NCIt 47 C3050
UMLS 69 C0017150

Summaries for Gastrinoma

Disease Ontology : 12 A neuroendocrine tumor that results_in an overproduction of gastric acid.

MalaCards based summary : Gastrinoma, also known as gastrin secreting tumor, is related to gastric gastrinoma and duodenal gastrinoma. An important gene associated with Gastrinoma is MEN1 (Menin 1), and among its related pathways/superpathways are Signaling by GPCR and Gastric acid production. The drugs SecreFlo and Dexlansoprazole have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and testes, and related phenotype is endocrine/exocrine gland.

Wikipedia : 72 A gastrinoma is a tumor in the pancreas or duodenum that secretes excess of gastrin leading to... more...

Related Diseases for Gastrinoma

Diseases related to Gastrinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
id Related Disease Score Top Affiliating Genes
1 gastric gastrinoma 31.7 CHGA GAST SST VIP
2 duodenal gastrinoma 12.0
3 pancreatic gastrinoma 12.0
4 zollinger-ellison syndrome 11.8
5 pancreatic neuroendocrine tumor 11.3
6 multiple endocrine neoplasia 1 10.8
7 mixed cell type adenoma of parathyroid 10.5 CHGA MEN1
8 autoimmune enteropathy 10.5 CHGA GAST
9 sparganosis 10.5 GAST SCT
10 brain stem ependymoma 10.5 CHGA MEN1
11 gorlin bushkell jensen syndrome 10.5 CHGA GAST
12 pemphigus foliaceus 10.4 MEN1 SST
13 mononeuritis of upper limb and mononeuritis multiplex 10.4 MEN1 SST
14 perianal skin paget's disease 10.4 CHGA GAST
15 nutritional optic neuropathy 10.4 GAST SST
16 substance-induced psychosis 10.4 GAST INS
17 perianal hematoma 10.4 GAST SST
18 duodenitis 10.4
19 mental retardation, autosomal recessive 53 10.4 GAST SST
20 strabismus 10.4 MEN1 SST
21 migraine with aura 10.4 MEN1 SST
22 early-onset parkinson disease 10.4 MEN1 SST
23 maturity-onset diabetes of the young, type 10 10.3 INS SCT
24 color blindness 10.3 GAST SST
25 tooth erosion 10.3 SCT SST
26 cardiovascular organ benign neoplasm 10.3 MEN1 SST
27 multiple endocrine neoplasia 10.3
28 sporadic hemiplegic migraine 10.3 CHGA MEN1
29 pancreatitis 10.3
30 renal pelvis carcinoma 10.3 CHGA SST
31 rete ovarii cystadenofibroma 10.3 CHGA SST
32 psychogenic movement 10.3 MEN1 SST
33 parathyroid oncocytic adenoma 10.3 CHGA MEN1
34 lactose intolerance 10.3 SCT SST
35 hepatitis 10.3
36 group b strep disease in newborns 10.3 CHGA INS
37 vestibular gland benign neoplasm 10.3 MEN1 SST
38 cervical keratinizing squamous cell carcinoma 10.3 INS SST
39 repetitive stress injuries 10.3 INS SST
40 fibrosarcomatous osteosarcoma 10.2 GAST SST
41 plantar fascial fibromatosis 10.2 CHGA GAST
42 protein s deficiency 10.2 INS SST
43 pericardial tuberculosis 10.2 CHGA INS
44 tamoxifen-related endometrial lesion 10.2 GAST MEN1 SCT
45 extrahepatic bile duct papillary adenoma 10.2 GAST MEN1 SCT
46 paraganglioma 10.2 CHGA SST
47 neurogenic arthropathy 10.1 INS SST
48 acute myocarditis 10.1 INS SST
49 subserous uterine fibroid 10.1 CHGA GAST MEN1
50 pituitary adenoma, acth-secreting 10.1 MEN1 SST

Graphical network of the top 20 diseases related to Gastrinoma:



Diseases related to Gastrinoma

Symptoms & Phenotypes for Gastrinoma

MGI Mouse Phenotypes related to Gastrinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.02 CHGA GAST INS MEN1 VIP

Drugs & Therapeutics for Gastrinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
SecreFlo 17 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002

Drugs for Gastrinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved Phase 4,Phase 1 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4,Phase 1 103577-45-3 3883
3
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
4
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
5 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
6 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
7 Antacids Phase 4,Phase 3,Phase 2,Phase 1
8 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
10
Proton pump inhibitors Phase 4,Phase 3,Phase 2,Phase 1
11
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
12
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
13
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
14
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
15
Esomeprazole Approved, Investigational Phase 3,Phase 1 161796-78-7, 119141-88-7 4594 9579578
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
19 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
20 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
21 Antimetabolites Phase 2, Phase 3,Phase 1
22 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
23 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
24 Calcimimetic Agents Phase 3
25 Calcium, Dietary Phase 3,Phase 2,Phase 1
26 Cinacalcet Hydrochloride Phase 3
27 Hormone Antagonists Phase 3,Phase 2,Phase 1
28 Hormones Phase 3,Phase 2,Phase 1
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
30 Adjuvants, Anesthesia Phase 3
31 Analgesics Phase 3
32 Analgesics, Opioid Phase 3
33 Anesthetics Phase 3
34 Anesthetics, General Phase 3
35 Anesthetics, Intravenous Phase 3
36 Central Nervous System Depressants Phase 3
37 Narcotics Phase 3
38 Peripheral Nervous System Agents Phase 3
39 Folate Nutraceutical Phase 2, Phase 3
40 Vitamin B9 Nutraceutical Phase 2, Phase 3
41 Cola Nutraceutical Phase 3,Phase 1
42
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
43
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
44
Pancrelipase Approved Phase 2,Phase 1 53608-75-6
45
Streptozocin Approved Phase 2 18883-66-4 29327
46
Omeprazole Approved, Investigational, Vet_approved Phase 2,Phase 1 73590-58-6 4594
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
49
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
50
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 54)

id Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
3 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
4 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
5 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3 Esomeprazole magnesium (Nexium)
6 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
7 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
10 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
11 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
12 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
13 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
14 Effect of G17DT in Patients With Stage II/III Colorectal Cancer Completed NCT02518373 Phase 2 Omeprazole
15 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
16 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
17 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
18 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
19 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
20 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
21 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
22 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
23 EPO906 in Carcinoid and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
24 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
25 Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
26 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
27 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
28 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2 YF476
29 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
30 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
31 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
32 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
33 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
34 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
35 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
36 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
37 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
38 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
39 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
40 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
41 A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants. Completed NCT00942175 Phase 1 Clopidogrel;Clopidogrel and Lansoprazole;Clopidogrel and Dexlansoprazole;Clopidogrel and Omeprazole;Clopidogrel and Esomeprazole
42 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
43 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1 everolimus;vatalanib
44 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
45 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
46 Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome Completed NCT00001254
47 Treatment of Zollinger-Ellison Syndrome Completed NCT00001241
48 Nexium Capsules Clinical Experience Investigation Completed NCT01434485
49 Evaluating Patients With Abnormal Levels of Gastric Acid Completed NCT00001240
50 Evaluation of the Prophylactic Use of Omeprazole in Patients Admitted to the State Hospital of Américo Brasiliense Completed NCT02278432

Search NIH Clinical Center for Gastrinoma

Cochrane evidence based reviews: gastrinoma

Genetic Tests for Gastrinoma

Anatomical Context for Gastrinoma

MalaCards organs/tissues related to Gastrinoma:

39
Liver, Pancreas, Testes, Small Intestine, Lymph Node, Bone, Breast

Publications for Gastrinoma

Articles related to Gastrinoma:

(show top 50) (show all 426)
id Title Authors Year
1
Severe chronic diarrhoea secondary to primary lymph node gastrinoma. ( 28446479 )
2017
2
Duodenal Gastrinoma Discovered on Evaluation for Incidental Gastric Carcinoid. ( 28300688 )
2017
3
Acute kidney injury following vomiting and diarrhea after endoscopy in a duodenal gastrinoma patient. ( 28070096 )
2017
4
Gastrinoma ( 28722872 )
2017
5
Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma). ( 28626400 )
2017
6
Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). ( 28540972 )
2017
7
Primary lymph node gastrinoma: A single institution experience. ( 28705492 )
2017
8
Sporadic, Primary Lymph Node Gastrinoma. ( 27457843 )
2016
9
Medical management of gastrinoma in a cat. ( 28491421 )
2016
10
(68)Ga-DOTATOC-PET/CT for effective diagnosis and treatment of pancreatic tail gastrinoma with multiple liver metastases: a case report. ( 26743558 )
2016
11
Clinical treatment of gastrinoma: A case report and review of the literature. ( 27123130 )
2016
12
Synchronous Peripancreatic Lymph Node Gastrinoma and Gastric Neuroendocrine Tumor Type 2. ( 27209642 )
2016
13
Management of pancreatic gastrinoma associated with Von Hippel-Lindau disease: a case report. ( 27055912 )
2016
14
Metastatic gastrinoma with secretory differentiation to ACTH. ( 27060354 )
2016
15
Metastatic gastrinoma in the breast mimicking primary solid papillary carcinoma. ( 27342908 )
2016
16
The Selective Arterial Calcium Injection Test is a Valid Diagnostic Method for Invisible Gastrinoma with Duodenal Ulcer Stenosis: A Case Report. ( 27348901 )
2016
17
Primary lymph node gastrinoma: 2 cases and a review of the literature. ( 25623161 )
2015
18
Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle. ( 27408649 )
2015
19
Primary jejunal gastrinoma: a case report and review of the literature. ( 26546053 )
2015
20
Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma. ( 25625026 )
2015
21
Surgery for gastrinoma: Short and long-term results. ( 25748044 )
2015
22
Intraoperative Use of a Portable Large Field of View Gamma Camera and Handheld Gamma Detection Probe for Radioguided Localization and Prediction of Complete Surgical Resection of Gastrinoma: Proof of Concept. ( 26206636 )
2015
23
Primary Hepatic Gastrinoma. ( 26556475 )
2015
24
Laparoscopic-assisted pancreaticoduodenectomy in a child with gastrinoma. ( 26711921 )
2015
25
Impact of a novel 14a88bp MEN1 deletion in a patient with hyperparathyroidism and gastrinoma. ( 26191410 )
2015
26
Intraoperative near-infrared fluorescence visualization of theA duodenal gastrinoma in a patient withA Zollinger-Ellison syndrome. ( 26209566 )
2015
27
Diagnosis and preoperative tagging of duodenal gastrinoma by endoscopic ultrasound. ( 26492296 )
2015
28
Deletions of RDINK4/ARF enhancer in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors. ( 25003221 )
2014
29
Case of primary hepatic gastrinoma: Diagnostic usefulness of the selective arterial calcium injection test. ( 25145887 )
2014
30
An esophageal gastrointestinal stromal tumor in a patient with MEN1-related pancreatic gastrinoma: an unusual association and review of the literature. ( 25022420 )
2014
31
Metastatic gastrinoma in a pediatric patient with zollinger-ellison syndrome. ( 23426004 )
2014
32
Primary lymph node gastrinoma. A diagnosis of exclusion. A case for duodenotomy in the setting of a negative imaging for primary tumor: A case report and review of the literature. ( 25462049 )
2014
33
Misdiagnosed gastrinoma: A case report. ( 24932294 )
2014
34
An evaluation of chromogranin A versus gastrin and progastrin in gastrinoma diagnosis and control. ( 24796622 )
2014
35
Gastrinoma and neurofibromatosis type 2: the first case report and review of the literature. ( 24961548 )
2014
36
Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. ( 22743840 )
2013
37
Criteria for the glucagon provocative test in the diagnosis of gastrinoma. ( 22983734 )
2013
38
Multiple gastrinomas of the duodenum in a patient with sporadic Zollinger-Ellison syndrome. ( 23613167 )
2013
39
Laparoscopic resection for primary lymph node gastrinoma. ( 23591435 )
2013
40
Lymph nodes metastasis and recurrences justify an aggressive treatment of gastrinoma. ( 23417896 )
2013
41
Partial pancreaticoduodenectomy can provide cure for duodenal gastrinoma associated with multiple endocrine neoplasia type 1. ( 22580937 )
2013
42
Primary lymph node gastrinoma: a rare cause of abdominal pain in childhood. ( 23743959 )
2013
43
Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome. ( 24363522 )
2013
44
Gastroduodenal neuroendocrine neoplasms including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). ( 24431117 )
2013
45
Recurrence after surgical resection of gastrinoma: who, when, where and why? ( 22410712 )
2012
46
Endobronchial metastasis from gastrinoma of the pancreas. ( 22383575 )
2012
47
Visual vignette. Gastrinoma. ( 21940272 )
2012
48
Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. ( 22864882 )
2012
49
Primary hepatic gastrinoma presenting as vague gastrointestinal symptoms. ( 22605007 )
2012
50
Multiple giant duodenal ulcers associated with duodenal gastrinoma. ( 26181878 )
2012

Variations for Gastrinoma

Cosmic variations for Gastrinoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM22579 MEN1 small intestine,duodenum,carcinoid-endocrine tumour,gastrinoma c.256A>T p.I86F 6
2 COSM532 KRAS small intestine,duodenum,adenoma,intestinal c.38G>A p.G13D 3
3 COSM521 KRAS small intestine,duodenum,adenoma,intestinal c.35G>A p.G12D 3

Expression for Gastrinoma

Search GEO for disease gene expression data for Gastrinoma.

Pathways for Gastrinoma

Pathways related to Gastrinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 GAST INS MEN1 NMB SCT SST
2 9.64 GAST SCT VIP

GO Terms for Gastrinoma

Cellular components related to Gastrinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.35 CHGA GAST INS SCT SST
2 extracellular region GO:0005576 9.17 CHGA GAST INS NMB SCT SST

Biological processes related to Gastrinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway GO:0007186 9.46 GAST INS SST VIP
2 regulation of protein localization GO:0032880 8.96 INS VIP
3 cell-cell signaling GO:0007267 8.8 INS NMB SST

Molecular functions related to Gastrinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.1 GAST INS NMB SCT SST VIP

Sources for Gastrinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....